Core Viewpoint - The establishment of the ISO international standard for "Broken Wall Ganoderma Spore Powder" marks a significant advancement in the internationalization of traditional Chinese medicine (TCM) and sets a quality benchmark for the global market [1][2]. Group 1: Standardization and Internationalization - The ISO standard (ISO/TS 25006:2025) for "Broken Wall Ganoderma Spore Powder" was officially implemented, facilitating the entry of Zhejiang-produced traditional Chinese medicine into international markets [1]. - The standard fills a global quality regulation gap in the field of Ganoderma spore powder, providing a unified measurement system for the industry [1][3]. - The standard includes specifications for raw material sources, a minimum breaking rate of 95%, and a multi-index quality control system for active components [1][2]. Group 2: Industry Growth and Economic Impact - Following the implementation of previous ISO standards for Ganoderma and Dendrobium, international trade volumes for these products increased by 284.5% and 37.5% respectively [3]. - The Zhejiang province's TCM industry is projected to achieve significant growth, with industrial output, new product output, and export scale expected to reach 5 times, 6.3 times, and 2.7 times the levels of 2005 by 2024 [3]. Group 3: Research and Development - The company has established a robust research platform, collaborating with various international institutions to enhance product technology and gather internationally recognized scientific data [2][3]. - The company has led the development of over 100 TCM standards, including 8 international standards, with several recognized by countries like the UK and Germany [2]. Group 4: Future Directions - Experts suggest that the next step for TCM is to develop a comprehensive standard system covering the entire industry chain, including cultivation, processing, quality inspection, and clinical evaluation [4]. - The company aims to continue its efforts in international standard formulation and promote more local medicinal materials globally, enhancing cooperation with countries along the Belt and Road Initiative [4].

Core Viewpoint - The release of the ISO international standard for "Broken Wall Ganoderma Spore Powder" marks a significant advancement in the standardization of traditional Chinese medicine (TCM), promoting quality and international development in the industry [1][2][4]. Group 1: Standardization and Innovation - The ISO standard (ISO/TS 25006:2025) for "Broken Wall Ganoderma Spore Powder" will be implemented in July 2025, following previous standards for other TCM products [2]. - The standard establishes key parameters such as raw material sources, a minimum 95% breaking rate, and a multi-index quality control system, enhancing production technology standardization [4]. - Experts emphasize that TCM standardization is a process of deriving scientific rules from clinical practices to form internationally recognized standards [4]. Group 2: Economic Impact - The implementation of ISO standards has led to significant increases in international trade, with related products seeing trade growth of 284.5% and 37.5% for Ganoderma and Dendrobium, respectively [5]. - The standards have been adopted in 31 countries, including major markets like the US, Canada, Australia, and Germany, facilitating trade recognition [5]. Group 3: International Collaboration - Collaborations with international institutions, such as clinical research on TCM's anti-tumor effects and cardiovascular benefits, are enhancing the scientific basis for standardization [6]. - The Zhejiang provincial government plans to strengthen the internationalization of TCM standards, focusing on local medicinal materials and specialty TCM products [6]. Group 4: Future Directions - The establishment of a comprehensive standard system covering the entire industry chain, from cultivation to clinical evaluation, is seen as essential for enhancing the industry's competitiveness [7]. - The company aims to deepen international standard formulation and promote local medicinal materials globally, particularly in countries along the Belt and Road Initiative [9].

Group 1 - Since January 2026, the A-share market has seen a wave of shareholder return activities, with 8 listed companies announcing various ways to reward investors, including physical gifts, discount coupons, and service rights [1][2] - This trend reflects the maturation of the Chinese capital market, indicating a diversification in how listed companies reward investors and a shift towards emotional connection and long-term value recognition in investor relations management [1][3] - Companies like Chen Ke Ming Food Co., Ltd. and Zhejiang Shou Xian Gu Pharmaceutical Co., Ltd. have initiated shareholder return activities, offering free products to shareholders based on their holdings [1][2] Group 2 - Other companies such as Quanjude Group, Furui Group, and Panda Dairy have also launched shareholder return activities in January, expressing gratitude to shareholders through various means [2] - The strategy of using products or services to reward shareholders enhances their perception of the company's value and fosters trust and long-term investment willingness, while also serving as a platform for brand promotion [2][3] - Over the past decade, more than 70 listed companies in the A-share market have conducted shareholder return activities, with over 30 companies doing so in 2025 across various sectors including consumer, cultural tourism, medical, and technology [2]

证券日报网讯1月29日，寿仙谷（603896）在互动平台回答投资者提问时表示，公司已关注到股吧相关 舆情信息。公司始终尊重所有投资者的交流权利，平等对待所有投资者，所有可能对公司股票交易价格 产生较大影响的重大信息，均会严格按照规定，通过法定媒体(如上海证券交易所网站及《上海证券 报》等)及公司官方渠道予以发布。非官方网络信息来源与动机多样，其真实性与客观性敬请投资者谨 慎甄别。 ...

（编辑 袁冠琳） 证券日报网讯 1月28日，寿仙谷在互动平台回答投资者提问时表示，公司高度重视人工智能技术与中医 药全产业链的融合应用，围绕全产业链数智工程体系建设顶层规划，已将AI技术不同程度地应用于育 种、研发、生产、营销等各核心环节：目前，公司构建了全球最大灵芝种质信息库，利用数字化模拟育 种、表型数据自动采集设备进行精准选育，实现生物育种从实验驱动向数据驱动转变；运用AI预测模 型、图像识别等技术打造智慧农场，实现中药材生长环境的精准调控和智能质检；自主研发基于大模型 定制的客服问答机器人，搭建AI动态知识引擎，通过AI技术优化运营流程，降低人力成本；利用AI技 术分析多渠道数据，构建包含年龄、体质、消费偏好等维度的用户画像，助力精准广告投放和个性化产 品组合推荐，实现产品研发与市场需求的动态匹配。未来，公司将持续深化"AI+中医药"的融合创新， 进一步推动全产业链的智能化升级，为公司高质量发展持续赋能。 ...

序号股东名称持股比例1杭州谷富企业管理有限公司70%2浙江寿仙谷投资管理有限公司30% 天眼查显示，近日，杭州寿仙谷商业发展有限公司成立，法定代表人为李振宇，注册资本10000万人民 币，杭州谷富企业管理有限公司、浙江寿仙谷投资管理有限公司持股。 企业名称杭州寿仙谷商业发展有限公司法定代表人李振宇注册资本10000万人民币国标行业租赁和商务 服务业>商务服务业>综合管理服务地址浙江省杭州市上城区明石路515号明石商业大厦9楼9137室企业 类型有限责任公司(自然人投资或控股)营业期限2026-1-27至无固定期限登记机关杭州市上城区市场监督 管理局 经营范围含商业综合体管理服务；企业管理；企业管理咨询；非居住房地产租赁；社会经济咨询服务； 信息技术咨询服务(除依法须经批准的项目外，凭营业执照依法自主开展经营活动)。 来源：市场资讯 ...

Group 1 - The core point of the article is that multiple listed companies, including Furi Co., are launching shareholder reward activities to enhance investor relations and provide incentives for holding shares [1][2][4][5] Group 2 - Furi Co. announced a shareholder reward activity where shareholders holding 10000 shares or more as of January 21 can participate [1][3] - Shareholders with 200,000 shares or more will receive gift boxes valued at 5000 yuan, while those with 10,000 to 200,000 shares will receive gift boxes valued at 500 yuan [3] - The activity will take place from January 28 to January 30, and shareholders must apply personally or designate a representative to claim their gifts [3] Group 3 - Other companies like Shouxiangu, Haoxiangni, and Suyanjingshen are also engaging in similar shareholder reward activities, offering exclusive products at discounted prices [2][4][5] - Shouxiangu is providing special purchase options for its products during the Spring Festival, while Haoxiangni is offering exclusive gift boxes at reduced prices for shareholders [4] - Suyanjingshen is celebrating its 10th anniversary by offering free experience gift boxes to shareholders who provide feedback on the company's development [5] Group 4 - Furi Co.'s main business includes home textile and new materials, with a reported revenue of 3.841 billion yuan for the first three quarters of 2025, a decrease of 4.45% year-on-year, and a net profit of 296 million yuan, down 12.05% year-on-year [3]

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2026-002 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 关于 2026 年春节股东回馈活动的公告 活动期间，公司股东及股东代表可以按股东专属优惠价格购入以下产品，每 个产品每人限购 2 份。 | 产品名称 | 原价 | 股东尊享价 | | --- | --- | --- | | 寿仙谷牌破壁灵芝孢子粉片-去壁款 （6 片*10 支/盒）3 盒/份 | 元 5940 | 元 4158 | | 寿仙谷无糖铁皮枫斗颗粒（2g*10 包/盒）3 盒/份 | 元 894 | 元 589 | | 寿仙谷铁皮枫斗灵芝浸膏（130g/瓶）1 瓶/份 | 元 3760 | 元 2629 | 四、活动参与方式 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 值此丙午马年新春佳节来临之际，为切实落实长效、多样的股东回报机制， 感恩广大股东长期以来对浙江寿仙谷医药股份有 ...

寿仙谷公告称，为落实股东回报机制，公司将开展2026年春节股东回馈活动。参与范围为截至2025年指 定日期收市后登记在册的股东，自然人股东仅限本人，法人股东限指定不超规定人数代表。活动期间， 股东可按专属优惠价购产品，如寿仙谷牌破壁灵芝孢子粉片-去壁款3盒/份，原价5940元，股东尊享价 4158元，每人限购1份。活动有指定参与及咨询方式，且不属于利润分配，对经营无重大影响。 ...

Group 1 - The company is actively developing a combination of traditional Chinese medicine culture and industrial tourism, focusing on health and wellness business [1] - The company successfully operates the Shouxiangu Organic Traditional Chinese Medicine Health Garden, which has been approved as a national 3A-level tourist attraction by the end of 2024 [1] - The company is working on a higher standard Shouxiangu Yanglong Health Industry Park, aiming for a 4A-level industrial tourism site [1] Group 2 - The Shouxiangu scenic area is not an asset operated by the company [1] - The company has engaged renowned traditional Chinese medicine practitioners to provide consultations at the Shouxiangu Traditional Medicine Hall, but online consultations are not yet available [1]